Treatment and prevention of cytomegalovirus in renal transplant patients: weighing the evidence.
Dalhousie University, Halifax, Nova Scotia.
Alison
A
Hakkert
Jennifer
J
Dykeman-Sharpe
D000998:Antiviral Agents / Q000627:therapeutic use; D019985:Benchmarking; D003586:Cytomegalovirus Infections / Q000188:drug therapy* / Q000209:etiology / Q000517:prevention & control*; D019317:Evidence-Based Medicine; D015774:Ganciclovir / Q000627:therapeutic use; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D017053:Infection Control / Q000379:methods / Q000592:standards; D016030:Kidney Transplantation / Q000009:adverse effects*; D018579:Patient Selection; D011182:Postoperative Care / Q000379:methods; D017410:Practice Guidelines as Topic; D012307:Risk Factors; D016896:Treatment Outcome
D000998:Antiviral Agents; D016756:Immunoglobulins, Intravenous; D015774:Ganciclovir